Medtronic PLC vs Abrdn Physical Platinum Shares ETF — how do they compare? Medtronic PLC trades at $87.9 (market cap $109.38B), while Abrdn Physical Platinum Shares ETF trades at $15.23 (market cap $1.93B). The key difference: Medtronic PLC is far larger — about 56.7× Abrdn Physical Platinum Shares ETF's market cap, and Medtronic PLC pays a 3.37% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| MDT | PPLT | |
|---|---|---|
Market Cap | $109.38B | $1.93B |
Volume | 55,890,185 | 2,947,556 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $105.35 | $25.23 |
52-Week Low | $73.75 | $13.73 |
Typical Hold Time | 63 Days | 42 Days |
Enterprise Value | $128.71B | — |
Dividend Yield | 3.37% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →